anti-BRAF (V600E) (human) Rabbit Monoclonal (RM8) (Biotin)

Proto-oncogene B-Raf; p94; v-Raf Murine Sarcoma Viral Oncogene Homolog B1; Serine/threonine-protein Kinase B-raf

1 mg/ml

32160000

liquid

Liquid. 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide.

Avoid freeze/thaw cycles.

A peptide corresponding to BRAF V600E mutant.

Biotin

Recombinant Antibody. This antibody reacts to the BRAF V600E mutant. No cross reactivity with wild type BRAF. Applications: ELISA, ICC, IHC, WB. Clone: RM8. Isotype: Rabbit IgG. Formulation: Liquid. 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide. BRAF is a human gene that encodes a protein called B-Raf. B-Raf is a member of the Raf kinase family of growth signal transduction protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation and secretion. Mutations in the BRAF gene can cause birth defects (inherited) or cancer, as an oncogene. Mutations in this gene have been found in cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, papillary thyroid carcinoma, non-small-cell lung carcinoma, adenocarcinoma of the lung, brain tumors including glioblastoma and Pleomorphic Xanthoastrocytomas as well as inflammatory diseases like erdheim-chester disease. The majority (>90%) of BRAF mutant cancers harbor the V600E mutation. The mutation leads to activation of the MAPK signaling pathway that increases cell invasion and reduces apoptosis. It also leads to reduced expression of melanocyte differentiation antigens and subsequent immune evasion.

P15056

Vial

BRAF is a human gene that encodes a protein called B-Raf. B-Raf is a member of the Raf kinase family of growth signal transduction protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation and secretion. Mutations in the BRAF gene can cause birth defects (inherited) or cancer, as an oncogene. Mutations in this gene have been found in cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, papillary thyroid carcinoma, non-small-cell lung carcinoma, adenocarcinoma of the lung, brain tumors including glioblastoma and Pleomorphic Xanthoastrocytomas as well as inflammatory diseases like erdheim-chester disease. The majority (>90%) of BRAF mutant cancers harbor the V600E mutation. The mutation leads to activation of the MAPK signaling pathway that increases cell invasion and reduces apoptosis. It also leads to reduced expression of melanocyte differentiation antigens and subsequent immune evasion.

Protein A purified.

Rabbit

This antibody reacts to the BRAF V600E mutant. No cross reactivity with wild type BRAF.

Non-hazardous

Primary Antibodies

12352203

Stable for at least 1 year after receipt when stored at -20°C.